- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Tvardi Therapeutics Inc (TVRD)
Tvardi Therapeutics Inc stock price live, this page displays NASDAQ TVRD stock exchange data. View the TVRD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Tvardi Therapeutics Inc real time stock price chart below.
What Is the Tvardi Therapeutics Inc Stock Price Today?
The Tvardi Therapeutics Inc stock price today is 24.1300.
What Is the Stock Symbol for Tvardi Therapeutics Inc?
The stock symbol for Tvardi Therapeutics Inc is ""TVRD.""
What Stock Exchange Does Tvardi Therapeutics Inc Trade On?
Tvardi Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Tvardi Therapeutics Inc a Good Stock to Buy?
Determining whether Tvardi Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TVRD quote. (ISIN: US1407553072)
What Is the Tvardi Therapeutics Inc Stock Price Today?
The Tvardi Therapeutics Inc stock price today is 24.1300.
What Is the Stock Symbol for Tvardi Therapeutics Inc?
The stock symbol for Tvardi Therapeutics Inc is ""TVRD.""
What Stock Exchange Does Tvardi Therapeutics Inc Trade On?
Tvardi Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Tvardi Therapeutics Inc a Good Stock to Buy?
Determining whether Tvardi Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TVRD quote. (ISIN: US1407553072)
24.1300
+0.2050(+0.86%)
Closed·
After Hours
24.0000-0.1300(-0.54%)
·
Fair Value
An estimate of a Tvardi Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.7402
24.7510
52 wk Range
8.1252
34.3100
TVRD Scorecard
Full Analysis
Suffers from weak gross profit margins
TVRD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Tvardi Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.740224.7510
52 wk Range
8.125234.3100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TVRD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Tvardi Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
56.4286
Upside
+133.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Form 8K Tvardi Therapeutics Inc For: 14 July
- Investing.com
- Form 8K Tvardi Therapeutics Inc For: 14 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Tvardi Therapeutics Inc Company Profile
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics Inc SWOT Analysis
Strategic Pivot | Cara Therapeutics refocuses on oral difelikefalin for notalgia paresthetica, streamlining operations amidst challenges with Korsuva commercialization |
Financial Outlook | Despite Q1 2024 losses, Cara projects cash reserves to fund operations into 2026, aligning with crucial KOURAGE Phase III study results timeline |
KOURAGE Trial Impact | Upcoming Part A results of KOURAGE Phase 3 trial viewed as critical inflection point, with potential to significantly boost investor confidence |
Market Potential | Analysts project peak sales of $630M by 2035 for oral DFK in notalgia paresthetica, with price targets ranging from $1 to $10 per share |
Tvardi Therapeutics Inc Earnings Call Summary for Q4/2023
- Cara Therapeutics focuses on notalgia paresthetica treatment, with Phase 2/3 COURAGE I study results expected in Q3 2023
- Cash runway extended into 2026 despite anticipated restrictions on KORSUVA injection due to reimbursement changes
- Company considering partnership opportunities for future business development amid reduced demand for KORSUVA in the US
- Cash and equivalents decreased to $100.8 million from $156.7 million in 2022; G&A expenses flat at $6.6 million for Q4 2023
- Management confident in clinical and commercial potential of NP program, prioritizing resources on neuropathic pruritus
Last Updated: 05/03/2024, 11:16
Read Full TranscriptCompare TVRD to Peers and Sector
Metrics to compare | TVRD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTVRDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | −0.5x | −0.5x | |
PEG Ratio | - | 0.00 | 0.00 | |
Price/Book | −2.2x | 0.9x | 2.6x | |
Price / LTM Sales | - | 1.4x | 3.3x | |
Upside (Analyst Target) | 127.9% | 238.0% | 42.9% | |
Fair Value Upside | Unlock | −1.7% | 6.2% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 56.4286
(+133.85% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-3.22 / -0.20
Revenue / Forecast
2.57M / 1.20M
People Also Watch
FAQ
What Stock Exchange Does Tvardi Therapeutics Trade On?
Tvardi Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Tvardi Therapeutics?
The stock symbol for Tvardi Therapeutics is "TVRD."
What Is the Tvardi Therapeutics Market Cap?
As of today, Tvardi Therapeutics market cap is 221.73M.
What Is Tvardi Therapeutics's Earnings Per Share (TTM)?
The Tvardi Therapeutics EPS (TTM) is -5.43.
From a Technical Analysis Perspective, Is TVRD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Tvardi Therapeutics Stock Split?
Tvardi Therapeutics has split 2 times.
How Many Employees Does Tvardi Therapeutics Have?
Tvardi Therapeutics has 12 employees.
What is the current trading status of Tvardi Therapeutics (TVRD)?
As of 12 Aug 2025, Tvardi Therapeutics (TVRD) is trading at a price of 24.13, with a previous close of 23.93. The stock has fluctuated within a day range of 22.74 to 24.75, while its 52-week range spans from 8.13 to 34.31.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.